

REMARKS

The office action of November 25, 2008 presents the examination of claims 11-26 and 30-40.

The sole grounds of rejection are for lack of enablement of claims 11-26 and 30-40. The Examiner asserts that the state of the art at the time of filing of the application was such that only claims directed to culture of mouse pluripotent stem cells in a medium comprising leukemia inhibitory factor (LIF), an antioxidant, and an inhibitor of adenylate cyclase activity.

While Applicants do not particularly agree with the Examiner, the claims have been so amended. Applicants reserve the right to file an application directed to the broader subject matter in an application filed pursuant to 35 USC § 120.

The favorable action of allowance of the pending claims is requested.

Should there be any outstanding matters that can to be resolved by a telephone conversation, the Examiner is respectfully requested to contact Mark J. Nuell, Registration No. 36,623 at the telephone number of the undersigned below, to expedite prosecution in connection with the present application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: March 25, 2008

Respectfully submitted,

By 
Mark J. Nuell

Registration No.: 36,623

BIRCH, STEWART, KOLASCH & BIRCH, LLP

12770 High Bluff Drive, Suite 260

San Diego, California 92130

(858) 792-8855

Attorney for Applicant